Richard Shea
Directeur/Bestuurslid bij SYNLOGIC, INC.
Vermogen: 930 $ op 30-04-2024
Actieve functies van Richard Shea
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SYNLOGIC, INC. | Directeur/Bestuurslid | 28-08-2017 | - |
Independent Dir/Board Member | 28-08-2017 | - | |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Directeur/Bestuurslid | - | - |
Loopbaan van Richard Shea
Eerdere bekende functies van Richard Shea
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SYNDAX PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | - | 13-07-2020 |
Directeur/Bestuurslid | 23-01-2014 | 13-02-2017 | |
Financieel Directeur/CFO | 13-02-2017 | 13-07-2020 | |
Independent Dir/Board Member | 23-01-2014 | 13-02-2017 | |
Treasurer | 13-02-2017 | 13-07-2020 | |
MOMENTA PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 01-07-2007 | 10-03-2015 |
Financieel Directeur/CFO | 01-10-2003 | 01-12-2016 | |
Variagenics, Inc.
Variagenics, Inc. Miscellaneous Commercial ServicesCommercial Services Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care through both biopharmaceutical collaborations and its own internal research programs | Operationeel Directeur | 01-02-1999 | 01-04-2003 |
Financieel Directeur/CFO | 01-02-1999 | 01-04-2003 | |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Financieel Directeur/CFO | 01-01-1992 | 01-01-1999 |
Opleiding van Richard Shea
Boston University | Masters Business Admin |
Princeton University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 9 |
Operationeel
Director/Board Member | 4 |
Director of Finance/CFO | 4 |
Independent Dir/Board Member | 2 |
Sectoraal
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
SYNDAX PHARMACEUTICALS, INC. | Health Technology |
SYNLOGIC, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Variagenics, Inc.
Variagenics, Inc. Miscellaneous Commercial ServicesCommercial Services Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care through both biopharmaceutical collaborations and its own internal research programs | Commercial Services |
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Beurs
- Insiders
- Richard Shea
- Ervaring